Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation

Therapeutic Drug Monitoring

Volumn 33, Issue 2, 2011, Pages 178-184

  Bouamar, Rachida ^a   Hesselink, Dennis A ^a   Van Schaik, Ron H N ^a   Weimar, Willem ^a   MacPhee, Iain A M ^b   De Fijter, Johan W ^c   Gelder, Teun Van ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ABCB1; cyclosporine; CYP3A; kidney transplantation; pharmacogenetics; pharmacokinetics

Indexed keywords

CREATININE; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GENOMIC DNA; GLUCOCORTICOID; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DELAYED GRAFT FUNCTION; DRUG DOSE TITRATION; DRUG EFFICACY; EVENING DOSAGE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GRAFT SURVIVAL; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MORNING DOSAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

CREATININE; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DELAYED GRAFT FUNCTION; FEMALE; GENOTYPE; GLUCOCORTICOIDS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERNATIONALITY; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 79953171482     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31820feb8e     Document Type: Article

References (39)

1. Hesselink DA, Smak Gregoor PJ, et al. The use of cyclosporine in renal transplantation. Transplant Proc. 2004;36:S99-S106.
2. Perna A, Gotti E, de Bernardis E, et al. A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicity. J Am Soc Nephrol. 1996;7: 786-791. (Pubitemid 27466013)
3. Benet LZ. The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm. 2009;6:1631-1643.
4. de Jonge H, Kuypers DR. Pharmacogenetics in solid organ transplantation: current status and future directions. Transplant Rev (Orlando). 2008;22:6-20. (Pubitemid 350131580)
5. Johne A, Kopke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther. 2002;72:584-594. (Pubitemid 36237730)
6. Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, et al. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther. 2008;84:457-461.
7. Yates CR, Zhang W, Song P, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol. 2003;43:555-564. (Pubitemid 36613114)
8. Kreutz R, Zurcher H, Kain S, et al. The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics. 2004;14: 665-671. (Pubitemid 39411266)
9. Fredericks S, Jorga A, MacPhee IA, et al. Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. Clin Transplant. 2007;21:252-257. (Pubitemid 46505735)
10. Kreutz R, Bolbrinker J, van der Sman-de Beer F, et al. CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine. Pharmacogenomics J. 2008;8: 416-422.
11. Zhu HJ, Yuan SH, Fang Y, et al. The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis. Pharmacogenomics J. 2010 Apr 6 [Epub ahead of print].
12. Hesselink DA, van Gelder T, van Schaik RH, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther. 2004;76:545-556. (Pubitemid 39601545)
13. Anglicheau D, Thervet E, Etienne I, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther. 2004;75:422-433. (Pubitemid 38534563)
14. Cattaneo D, Ruggenenti P, Baldelli S, et al. ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J Am Soc Nephrol. 2009;20:1404-1415.
15. von Ahsen N, Richter M, Grupp C, et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-Vallele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem. 2001;47:1048-1052. (Pubitemid 32493590)
16. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245-254. (Pubitemid 37083100)
17. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004;14:147-154. (Pubitemid 38373108)
18. Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol. 2005;16: 1501-1511. (Pubitemid 41716536)
19. Chowbay B, Cumaraswamy S, Cheung YB, et al. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics. 2003;13:89-95. (Pubitemid 36259588)
20. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant. 2005;5:987-994. (Pubitemid 40571246)
21. Picard N, Yee SW, Woillard JB, et al. The role of organic aniontransporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther. 2010;87: 100-108.
22. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the Fixed-Dose Concentration-Controlled trial. Transplantation. 2008;86:1043-1051.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
24. van Schaik RH, van der Heiden IP, van den Anker JN, et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002;48: 1668-1671.
25. Hesselink DA, van Schaik RH, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics. 2008;18:339-348. (Pubitemid 351367527)
26. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-391. (Pubitemid 32268418)
27. Grinyo J, Vanrenterghem Y, Nashan B, et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int. 2008;21:879-891.
28. Hesselink DA, van Dam T, Metselaar HJ, et al. The relative importance of cyclosporine exposure in heart, kidney or liver transplant recipients on maintenance therapy. Transpl Int. 2004;17:495-504. (Pubitemid 39592736)
29. Mottino AD, Catania VA. Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents. World J Gastroenterol. 2008;14: 7068-7074.
30. Fanta S, Jonsson S, Karlsson MO, et al. Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism. J Clin Pharmacol. 2010;50:581-597.
31. Press RR, Ploeger BA, den Hartigh J, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit. 2009;31:187-197.
32. Press RR, Ploeger BA, den Hartigh J, et al. Explaining variability in ciclosporin exposure in adult kidney transplant recipients. Eur J Clin Pharmacol. 2010;66:579-590.
33. Ohlman S, Lindholm A, Hagglund H, et al. On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation. Eur J Clin Pharmacol. 1993;44:265-269. (Pubitemid 23096155)
34. Goh CC, Ladouceur M, Peters L, et al. Lengthy cold ischemia time is a modifiable risk factor associated with low glomerular filtration rates in expanded criteria donor kidney transplant recipients. Transplant Proc. 2009;41:3290-3292.
35. Dominguez J, Lira F, Troncoso P, et al. Factors that predict duration of delayed graft function in cadaveric kidney transplantation. Transplant Proc. 2009;41:2668-2669.
36. Krajewska M, Koscielska-Kasprzak K, Weyde W, et al. Impact of donordependent genetic factors on long-term renal graft function. Transplant Proc. 2009;41:2978-2980.
37. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4:481-508.
38. Naesens M, Lerut E, de Jonge H, et al. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol. 2009;20:2468-2480.
39. Hesselink DA, Bouamar R, van Gelder T. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Ther Drug Monit. 2010;32: 387-393.